logo
Plus   Neg
Share
Email

West Pharmaceutical Services To Replace Helmerich & Payne In S&P 500

S&P Dow Jones Indices said that S&P MidCap 400 constituent West Pharmaceutical Services Inc. (WST) will replace Helmerich & Payne Inc. (HP) in the S&P 500.

Helmerich & Payne will replace J.C. Penney Company Inc. (JCP) in the S&P SmallCap 600, and Physicians Realty Trust (DOC) will replace West Pharmaceutical Services in the S&P MidCap 400.

S&P Dow Jones Indices stated that J.C. Penney filed to reorganize under Chapter 11 of the U.S. Bankruptcy Code and is no longer eligible for continued inclusion in the S&P SmallCap 600.

Helmerich & Payne has a market capitalization that is more representative of the small-cap market space.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year.
Follow RTT